Revolution Medicines said daraxonrasib met key endpoints in its pivotal Phase 3 pancreatic cancer trial, nearly doubling median overall survival versus standard chemotherapy in previously treated metastatic disease. The company indicated the interim analysis results will be treated as final and is weighing a swift regulatory path, supported by an FDA national priority voucher pilot designation already granted for the program. Shares and deal momentum followed quickly, with the company also moving to raise capital aggressively. On the heels of the clinical readout, Revolution priced a large concurrent stock and debt offering to capitalize on investor appetite. Taken together, the trial results and financing underscore how rapidly the market is reacting to pancreatic cancer efficacy signals, especially when they translate into potential priority-review timelines.